Annovis Bio Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
ANVS
- Share Price
-
$0.93
- (As of Friday Closing)
Annovis Bio General Information
Description
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Contact Information
Website
www.annovisbio.comCorporate Office
- 101 Lindenwood Drive
- Suite 225
- Malvern, PA 19355
- United States
Corporate Office
- 101 Lindenwood Drive
- Suite 225
- Malvern, PA 19355
- United States
Annovis Bio Timeline
Annovis Bio Stock Performance
As of 13-Nov-2026, Annovis Bio’s stock price is $0.93. Its current market cap is $39.8M with 43M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.93 | $0.85 | $0.62 - $5.50 | $39.8M | 43M | 1.73M | -$1.55 |
Annovis Bio Financials Summary
As of 30-Sep-2026, Annovis Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 35,473 | 76,414 | 56,763 | 185,550 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (52,274) | (29,553) | (24,922) | (56,872) |
| Net Income | (51,724) | (28,854) | (24,590) | (56,204) |
| Total Assets | 5,504 | 21,082 | 13,926 | 10,208 |
| Total Debt | 0 | 0 | 0 | 0 |
Annovis Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Annovis Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Annovis Bio Comparisons
Industry
Financing
Details
Annovis Bio Competitors (32)
One of Annovis Bio’s 32 competitors is IRulya Therapeutics, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IRulya Therapeutics | Formerly VC-backed | New Haven, CT | ||||
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| ZyVersa Therapeutics | Formerly VC-backed | Lighthouse Point, FL | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| TauRx Pharmaceuticals | Private Equity-Backed | Aberdeen, United Kingdom |
Annovis Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Annovis Bio Patents
Annovis Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025255358-A1 | Solid forms of posiphen d-tartrate and processes of preparation thereof | Pending | 06-Jun-2024 | ||
| AU-2024441370-A1 | Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor | Pending | 15-Apr-2024 | ||
| WO-2025221289-A1 | Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor | Pending | 15-Apr-2024 | ||
| AU-2024440707-A1 | Treatment of diseases via administration of buntanetap and an antihypertensive agent | Pending | 15-Apr-2024 | ||
| US-20250319068-A1 | Treatment of diseases via administration of buntanetap and an antihypertensive agent | Pending | 15-Apr-2024 | A61K31/517 |
Annovis Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Annovis Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.67 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Annovis Bio FAQs
-
When was Annovis Bio founded?
Annovis Bio was founded in 2008.
-
Where is Annovis Bio headquartered?
Annovis Bio is headquartered in Malvern, PA.
-
What is the size of Annovis Bio?
Annovis Bio has 7 total employees.
-
What industry is Annovis Bio in?
Annovis Bio’s primary industry is Drug Discovery.
-
Is Annovis Bio a private or public company?
Annovis Bio is a Public company.
-
What is Annovis Bio’s stock symbol?
The ticker symbol for Annovis Bio is ANVS.
-
What is the current stock price of Annovis Bio?
As of 13-Nov-2026 the stock price of Annovis Bio is $0.93.
-
What is the current market cap of Annovis Bio?
The current market capitalization of Annovis Bio is $39.8M.
-
Who are Annovis Bio’s competitors?
IRulya Therapeutics, CervoMed, ZyVersa Therapeutics, Alector, and TauRx Pharmaceuticals are some of the 32 competitors of Annovis Bio.
-
What is Annovis Bio’s annual earnings per share (EPS)?
Annovis Bio’s EPS for 12 months was -$1.55.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
